top of page
Browse by category
Search
New MRI technique identifies heart disease risk from fat composition
Researchers from the University of Virginia's (UVA) Department of Biomedical Engineering are seeking to use magnetic resonance imaging...
Genetically altered fat cells in mice show promise for obesity treatment
Obese mice whose fat cells were genetically altered to produce an increased amount of the glucose-dependent insulinotropic polypeptide...
Calorie content influences food choices regardless of obesity status after surgery
Higher calorie foods were preferred among individuals with and without obesity despite similar taste and texture, according to a study by...
Ratioing the resected gastric volume to the number of fired staplers predicts weight loss
Ratioing the resected gastric volume (RGV) to the number of staplers fired (SF) could be used to predict midterm weight loss, according...
Arrowhead initiates phase 1/2a study of ARO-INHBE for obesity
Arrowhead Pharmaceuticals has dosed the first subjects in a Phase 1/2a clinical trial of ARO-INHBE, the company’s investigational RNA...
Survey finds 93.4% of bariatric patients vs 51.4% of GLP-1 patients have the same treatment again
Over 93% of bariatric patients said they would undergo bariatric surgery again, compared with just over half of those who said they would...
Wave Life Sciences announces submission of first clinical trial application for WVE-007 in obesity
Wave Life Sciences has submitted its first clinical trial application (CTA) for WVE-007 in obesity. WVE-007 is an investigational...
Rhythm gains expanded indication for IMCIVREE (setmelanotide) for patients as young as 2 years old
Rhythm Pharmaceuticals has received an expanded indication for IMCIVREE (setmelanotide) to include children as young as 2 years old to...
REDEFINE 1 trial: CagriSema demonstrates superior weight loss in adults with obesity or overweight
Headline results from Novo Nordisk’s REDEFINE 1 has shown that the trial achieved its primary endpoint by demonstrating a statistically...
Zepbound (tirzepatide) is the first and only FDA approved prescription medicine for moderate-to-severe OSA in adults with obesity
The FDA has approved Eli Lilly and Company’s Zepbound (tirzepatide) as the first and only prescription medicine for adults with...
Browse by tag
bottom of page